我要投票 SHINVA新华在医疗器械行业中的票数:125
· 外 推 电 报 ·
2025-02-23 12:30:41 星期日

【SHINVA新华是哪个国家的品牌?】

SHINVA新华是什么牌子?「SHINVA新华」是 山东新华医疗器械股份有限公司 旗下著名品牌。该品牌发源于山东,由创始人许尚峰在1993期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力SHINVA新华品牌出海!通过在本页面挂载SHINVA新华品牌的产品链接和联系邮箱,可以提高SHINVA新华产品曝光!跨境电商爆单神器,目前只要100元/年哦~

2002年9月,山东新华医疗器械股份有限公司在上海证券交易所上市,现为中国医疗器械行业协会会长单位。

山东新华医疗器械股份有限公司始终坚持拼搏诚信的齐鲁文化、以用户为中心的现代企业文化为企业核心价值观,用目标鼓舞士气,用发展凝聚人心,用创新提升素质,用文化打造实力,坚定不移地走健康产业之路,坚定不移地走技术创新之路,坚定不移地走资本运作之路,拥有医疗器械及装备、制药装备、医疗服务三大业务板块。

在医疗器械板块,已形成九大配置精良、技术完备的先进产品线,涵盖感染控制、放疗及影像、手术器械及骨科、手术室工程及设备、口腔设备及耗材、体外诊断试剂及仪器、生物材料及耗材、透析设备及耗材、医用环保及其他领域。

制药装备板块,由生物制药、特种输液、中药制剂、固体制剂四大工程技术中心组成,下设八个产品技术分厂和五个控股公司,集制药装备研发、制造及销售为一体。在常规制药装备生产之外,提供着“制药工艺、制药装备、制药工程”三位一体的优质服务;同时,为化学药、生物药、植物药工厂的建设提供整包服务,为客户解决一切后顾之忧。

在医疗服务领域,新华医疗持续提升着品牌竞争力和美誉度。凭借专业的投资、建设、运营及采购和服务平台,打造具有先进医疗理念、前沿科研水平、品牌经营连锁、资源有机融合的现代化医院集团。与此同时,新华医疗也在积极拓展着肾脏健康服务,利用公司专业化、集约化、连锁化的运营优势,为医院提供新技术、新管理、新模式,创建出一系列特色鲜明的肾脏病专科医院和血液透析中心,用无限的责任感和专业度,服务于广大肾病患者。未来,新华医疗,将以集团化、专业化、规范化的全新面貌,为更多患者提供完善医疗服务,成就发展健康产业之路的宏伟梦想。

公司以山东核心区域为研发、制造、营销和管理总部,同时有北京核心区域、上海核心区域。

心系健康,诚信天下。站在新的历史起点上,面对新的发展机遇,新华医疗将一如既往,与时俱进,以自信、创新和拼搏,去勇敢面对困难和挑战,为人类健康事业、为铸造中国医疗器械产业的丰碑、打造世界知名医疗器械生产企业而继续努力奋斗!

英文翻译:In September 2002, Shandong Xinhua medical device Co., Ltd. was listed on the Shanghai Stock Exchange and is now the chairman of China Medical Device Industry Association. Shandong Xinhua Medical Equipment Co., Ltd. always adheres to the Qilu culture of striving for integrity, the modern enterprise culture centered on users as the core values of the enterprise, encourages morale with goals, rallies people with development, improves quality with innovation, builds strength with culture, firmly takes the road of health industry, firmly takes the road of technological innovation, and firmly takes the road of capital The way of operation, with medical devices and equipment, pharmaceutical equipment, medical services three business sectors. In the medical equipment sector, nine advanced product lines with excellent configuration and complete technology have been formed, covering infection control, radiotherapy and imaging, surgical equipment and orthopedics, operating room engineering and equipment, oral equipment and consumables, in vitro diagnostic reagents and instruments, biomaterials and consumables, dialysis equipment and consumables, medical environmental protection and other fields. The pharmaceutical equipment sector is composed of four engineering technology centers, including biopharmaceutical, special infusion, traditional Chinese medicine preparation and solid preparation. It has eight product technology branches and five holding companies, integrating the R & D, manufacturing and sales of pharmaceutical equipment. In addition to the production of conventional pharmaceutical equipment, it provides the high-quality service of "pharmaceutical technology, pharmaceutical equipment, pharmaceutical engineering"; at the same time, it provides the whole package service for the construction of chemical medicine, biological medicine, plant medicine factories, and solves all the worries for customers. In the field of medical services, Xinhua medical continues to enhance its brand competitiveness and reputation. With professional investment, construction, operation, procurement and service platform, we will build a modern hospital group with advanced medical concept, cutting-edge scientific research level, brand management chain and organic integration of resources. At the same time, Xinhua medical is also actively expanding kidney health services, taking advantage of the company's professional, intensive and chain operation advantages to provide new technology, new management and new mode for the hospital, creating a series of distinctive kidney disease specialized hospitals and hemodialysis centers, serving the vast number of nephrotic patients with unlimited sense of responsibility and professionalism. In the future, Xinhua medical will take a new look of collectivization, specialization and standardization to provide more patients with perfect medical services and achieve the grand dream of developing health industry. The company takes the core area of Shandong Province as its R & D, manufacturing, marketing and management headquarters, and has the core areas of Beijing and Shanghai. Heart health, integrity world. Standing at a new historical starting point and facing new development opportunities, Xinhua medical will, as always, keep pace with the times, bravely face difficulties and challenges with self-confidence, innovation and hard work, and continue to strive for the cause of human health, the building of a monument of China's medical device industry and the building of a world-famous medical device manufacturer!

本文链接: https://www.waitui.com/brand/f0c49f885.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

上海市副市长陈杰:加快建设人工智能“上海高地”,壮大开源社区力量

36氪获悉,2月23日,2025全球开发者先锋大会在上海徐汇召开,上海市副市长陈杰出席开幕式并发表致辞。陈杰指出,面对人工智能快速迭代、模型开源的新趋势,上海将继续发挥超大城市的综合优势,加快建设更具国际影响力的人工智能“上海高地”。进一步完善开源开放生态系统,夯实“语料开放+模型开源”服务体系,不断壮大开源社区力量,推动基础模型、算法和数据资源的共享与开放,构建开放协作、互利共赢的创新环境。(中国基金报)

31分钟前

清华AIR联合水木分子开源DeepSeek版多模态生物医药大模型BioMedGPT-R1

36氪获悉,清华大学人工智能产业研究院(AIR)和北京水木分子生物科技有限公司近日携手推出了升级版的生物医药多模态开源基础大模型BioMedGPT-R1。此前,在2023年,双方合作发布了开源可商用、生物医药多模态百亿参数开源基础大模型BioMedGPT,水木分子发布了自研千亿参数多模态生物医药专业大模型Chat DD-FM和新一代AI驱动药物发现工具Chat DD。这次DeepSeek版ChatDD- R1基座模型也已同步上线ChatDD,赋能生物医药企业的药物研发。

31分钟前

TCL李东生:中国制造未来在海外最大增量大概率来自新兴市场

36氪获悉,TCL&奥林匹克全球合作伙伴签约仪式近日在北京举行。会后,TCL创始人、董事长李东生接受记者采访时表示,当前全球产业链面临转移与重构,持续由全球化向区域化、本土化方向发展。中国制造未来在海外最大的增量空间大概率来自新兴市场,比如巴西等新兴经济体。目前TCL海外制造基地分布在越南、马来西亚、菲律宾、印尼、印度、巴基斯坦、波兰、墨西哥、巴西等九个国家,实现东南亚、南亚、欧洲、北美、南美等各大区域本土化制造布局。未来,会持续关注新兴市场的增长潜力。

31分钟前

深圳:来深毕业生免费7天住升级为15天

为方便各地高校毕业生来深找工作,深圳相继推出“青年驿站”“深梦启航”“深梦扬帆”等“深梦”系列公益活动,为各地来深高校毕业生提供免费7天居住福利,解决他们阶段性、过渡性的居住需求。 2月23日,深圳市政府新闻办召开“打造最好科技创新生态和人才发展环境”新闻发布会。市委科创委办公室主任、科技创新局局长张林在会上透露,深圳为高校应届毕业生来深求职提供免费住宿天数,将从7天延长到15天。 (深圳特区报)

31分钟前

湖南规范互联网医院处方行为:严禁使用AI等自动生成处方

36氪获悉,湖南省医保局近日发布《关于进一步加强基本医疗保障定点零售药店管理的通知》。通知中提到,规范互联网医院处方行为。对互联网医院处方有如下几个措施:①压实实体医疗机构责任。依托实体医疗机构与市级医保部门签订补充协议,强化实体医疗机构的管理责任,因互联网医院违规被解除补充协议的原则上同步解除实体医疗机构医保定点协议,依托的实体医疗机构原则上应为二级及以上医疗机构。②纳入医保管理范畴。在本统筹区提供处方服务的由本市医保中心签协议后公布,跨市州提供处方服务的先征得药店所在地市级医保中心同意,再报省医保中心审定公布。③接入处方流转平台。互联网医院须按规定接入省医保电子处方中心并进行电子处方流转。④明确处方要求。处方行为必须符合行业主管部门管理办法,应与患者或患者家属进行有效、充分的沟通问诊,严禁使用人工智能等自动生成处方。

31分钟前

本页详细列出关于海氏海诺的品牌信息,含品牌所属公司介绍,海氏海诺所处行业的品牌地位及优势。
咨询